Status | Study |
Recruiting |
Study Name: A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy Condition: Inflammatory Breast Cancer Malignant Neoplasm of Breast Date: 2016-11-21 Interventions: Drug: Pembrolizumab Pembrolizumab 200 mg administered on day 1 of each 3-week cycle as approximately 30 |
Not yet recruiting |
Study Name: Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer Condition: HER2/Neu Negative Recurrent Inflammatory Breast Carcinoma Date: 2016-09-02 Interventions: Biological: Ipilimumab Given I |
Recruiting |
Study Name: Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer Condition: Inflammatory Breast Cancer (IBC) Date: 2016-08-09 Interventions: Drug: Ruxolitinib 15 or 20 mg, |
Recruiting |
Study Name: A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer Condition: Inflammatory Breast Cancer Human Epidermal Growth Factor 2 Nega Date: 2015-12-02 Interventions: Drug: Eribulin administered IV |
Recruiting |
Study Name: MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC) Condition: Breast Cancer Date: 2015-04-03 Interventions: Drug: MK-3475 200 mg administe |
Recruiting |
Study Name: Nintedanib For HER2-negative Metastatic Inflammatory Breast Cancer (MIBC) Condition: Breast Cancer Date: 2015-03-10 Interventions: Drug: BIBF 1120 Initial dose i |
Completed |
Study Name: Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer Condition: Inflammatory Breast Cancer Date: 2014-12-14 Interventions: Drug: Docetaxel Drug: Cyclophosphamide |
Terminated |
Study Name: Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer Condition: HER2-negative Breast Cancer Inflammatory Breast Cancer Date: 2013-09-05 Interventions: Drug: Romidepsin Other Names: |
Recruiting |
Study Name: Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy Condition: Inflammatory Breast Carcinoma Date: 2013-06-25 Interventions: Drug: 89Zr-bevacizumab 89Zr-be |
Recruiting |
Study Name: Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer Condition: Inflammatory Breast Cancer Date: 2011-05-25 Interventions: Biological: Bevacizumab During |